At its meeting on February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG) for use in adults aged 18 and older. This vaccine is a two-dose series (0, 1 month) administered to prevent hepatitis B infection.
Key points from the February 2018 meeting regarding Hep B:
Heplisav-B (HepB-CpG) Recommendation: ACIP voted to recommend the use of Heplisav-B, a yeast-derived hepatitis B vaccine with a novel adjuvant, in adults aged 18 and older.
Two-Dose Series: The vaccine is administered as a two-dose series, with the second dose given one month after the first.
Adult Population: The recommendation specifically focuses on adults, with the ACIP recommending Heplisav-B for individuals aged 18 years and older who are recommended to be vaccinated against HBV.
This is why RFK Jr. Retired Every Member of ACIP
This clip from a 2018 ACIP meeting illustrates exactly why ACIP reform is necessary.
“Is there any comment on using this vaccine at the same time with other adjuvanted vaccines?”
“We have no data to make a recommendation one way or the other.”
They approved these injections without safety data is for real mind blowing…
Please watch and Listen to this video: